Janus Henderson Investors US’s ProQR Therapeutics PRQR Stock Holding History

Janus Henderson Investors US’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1.92M	Sell	383,821 -10,039	-3%	-$44.1K	﹤0.01%	933
2016 Q4	$1.93M	Sell	393,860 -8,236	-2%	-$42.4K	﹤0.01%	964
2016 Q3	$2.68M	Sell	402,096 -9,887	-2%	-$54.4K	﹤0.01%	908
2016 Q2	$1.99M	Sell	411,983 -16,178	-4%	-$83.2K	﹤0.01%	914
2016 Q1	$2.09M	Sell	428,161 -341,176	-44%	-$1.73M	﹤0.01%	906
2015 Q4	$6.68M	Sell	769,337 -2,475	-0.3%	-$28.5K	0.01%	778
2015 Q3	$11.2M	Sell	771,812 -143,764	-16%	-$2.41M	0.01%	698
2015 Q2	$15.3M	Sell	915,576 -197,992	-18%	-$3.73M	0.01%	645
2015 Q1	$24.4M	Buy	1,113,568 +367,043	+49%	+$7.58M	0.02%	582
2014 Q4	$16.2M	Buy	746,525 +47,687	+7%	+$724K	0.01%	632
2014 Q3	$12M	Buy	+698,838	New	+$11.2M	0.01%	661

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Janus Henderson Investors US's PRQR Position: Q1 2017 in Review

Janus Henderson Investors US reduced its ProQR Therapeutics (PRQR) stake by 2.5% in Q1 2017, selling an estimated $44.1K and leaving 383,821 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Janus Henderson Investors US first reported a position in PRQR in Q3 2014 and has held it in 11 quarters since. The position peaked at $24.4M in Q1 2015. 20 funds tracked by Wall St. Rank hold PRQR as of Q1 2017.

Janus Henderson Investors US held 383,821 shares of ProQR Therapeutics worth $1.92M as of Q1 2017.
Janus Henderson Investors US sold 10,039 ProQR Therapeutics shares in Q1 2017, an estimated $44.1K.
ProQR Therapeutics made up ﹤0.01% of Janus Henderson Investors US's portfolio in Q1 2017, its #933 holding.
Janus Henderson Investors US first reported a position in ProQR Therapeutics in Q3 2014 and has held it in 11 quarters since.
Janus Henderson Investors US's ProQR Therapeutics position peaked at $24.4M in Q1 2015.
20 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.